Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1-1b Study of [225Ac]Ac-A9-3408 in Unresectable or Metastatic Melanoma
NCT07076550Phase 1Terminated
- Sponsor
- Alpha-9 Oncology
- Start
- Nov 2025
- Primary completion
- Jul 2026
- Modality
- Alpha Emitters
- Countries
- 1
01
Overview
Phase 1, open-label trial of A9-3408 in melanoma (2 arms), sponsored by Alpha-9 Oncology. Primary endpoints: Maximum Tolerated Dose at 28 days, Recommended Phase 2 Dose at 28 days and 1 more. Started Nov 2025; status: terminated.
02
Drugs
A9-3408
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT07076550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07076550.